Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Division of Therapeutic Radiology and Oncology, Department of Radiology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
PLoS One. 2021 Oct 7;16(10):e0258186. doi: 10.1371/journal.pone.0258186. eCollection 2021.
To report the long-term local control and survival of patients with early breast cancer who had hypofractionated whole breast irradiation with concomitant boost (Hypo-CB).
Between October 2009 and June 2010, 73 patients with early breast cancer (T1-3N0-1M0) who underwent breast conserving surgery were enrolled into the study. Thirty-six of these participants received 50 Gy of conventional irradiation in 25 fractions over 5 weeks to the whole breast with a sequential boost to the tumor bed with 10-16 Gy in 5-8 fractions (Conv-SEQ). The other 37 participants received a hypofractionated dose of 43.2 Gy in 16 fractions with an additional daily concomitant boost (CB) of 0.6 Gy over 3 weeks (Hypo-CB).
At a median follow-up time of 123 months, ipsilateral local recurrence (ILR) was found in 3 participants, 1 of whom was in the hypofractionated group. All 3 ILR were true local recurrence (TR). There were no significant differences in the 10-year disease free survival (DFS) and 10-year overall survival rates (OS) between the conventional and hypofractionated groups (93.9% vs. 94.4%, p = 0.96 and 91.9% vs. 91.6%, p = 0.792, respectively).
This study showed that the effectiveness, DFS and OS were comparable between hypofractionated whole breast irradiation with a CB and the conventional irradiation with a sequential boost.
报告接受Hypo-CB（Hypofractionated Whole Breast Irradiation with concomitant boost）治疗的早期乳腺癌患者的长期局部控制和生存情况。
2009 年 10 月至 2010 年 6 月期间，共纳入 73 例接受保乳手术的早期乳腺癌（T1-3N0-1M0）患者参与本研究。其中 36 例患者接受常规照射，5 周内 25 次分割 50 Gy 照射全乳，序贯肿瘤床 10-16 Gy 5-8 次分割（Conv-SEQ）。另外 37 例患者接受 43.2 Gy 的 Hypo-CB 治疗，16 次分割，3 周内每天额外给予 0.6 Gy 的同步推量。
中位随访时间为 123 个月，3 例患者出现同侧局部复发（ILR），其中 1 例发生在 Hypo-CB 组。所有 3 例 ILR 均为真性局部复发（TR）。常规组和 Hypo-CB 组的 10 年无病生存率（DFS）和 10 年总生存率（OS）无显著差异（93.9% vs. 94.4%，p=0.96 和 91.9% vs. 91.6%，p=0.792）。
本研究表明，Hypo-CB 与常规序贯推量照射在有效性、DFS 和 OS 方面相当。
